Dermatomyositis increasingly failing treatment
Researchers writing in JAMA Dermatology find that most adult patients with dermatomyositis do not achieve satisfactory control of this disease, even with long-term aggressive therapy.
Dermatomyositis is an idiopathic inflammatory myopathy that manifests as inflammation of the skin, muscles, joints and lungs. It can lead to organ damage with extensive cutaneous disease. The skin is affected in cases of patients with classic myositis, patients who are clinically amyopathic, in patients who never develop muscle disease, and patients with persistent skin inflammation.
The goal of this study was to characterize the cutaneous disease course in adult patients.
Of 74 patients included in this prospective cohort study, 28 patients achieve clinical skin remission in a three-year follow-up period.
“Increasing age, having an associated malignancy, and treatment with mycophenolate mofetil were significantly associated with clinical remission of skin disease, while having anti–melanoma differentiation-associated gene 5 antibodies was significantly associated with worse outcomes,” researchers wrote.
Paige W. Wolstencroft, BA; Lorinda Chung, MD, MS; Shufeng Li, MS; et al. “Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis,” JAMA Dermatology, online first, Nov. 7, 2017. DOI: 10.1001/jamadermatol.2017.3758